Brokerages Set iTeos Therapeutics, Inc. (NASDAQ:ITOS) Target Price at $15.50

Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) have received an average recommendation of “Hold” from the seven research firms that are presently covering the company, MarketBeat.com reports. Six analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $15.50.

A number of research analysts have issued reports on the company. Wedbush restated an “outperform” rating and issued a $10.50 price objective (down previously from $12.00) on shares of iTeos Therapeutics in a research note on Monday, July 21st. Piper Sandler downgraded iTeos Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 21st. Wall Street Zen upgraded iTeos Therapeutics to a “sell” rating in a research note on Saturday, August 30th. Finally, Wells Fargo & Company reduced their price objective on iTeos Therapeutics from $12.00 to $11.00 and set an “equal weight” rating for the company in a research note on Thursday, August 7th.

iTeos Therapeutics Stock Performance

Shares of iTeos Therapeutics stock opened at $10.15 on Tuesday. The stock has a fifty day simple moving average of $10.16 and a 200 day simple moving average of $8.71. iTeos Therapeutics has a 12-month low of $4.80 and a 12-month high of $17.63. The company has a market capitalization of $448.73 million, a P/E ratio of -2.17 and a beta of 1.31.

iTeos Therapeutics (NASDAQ:ITOS) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($1.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.12) by ($0.39). On average, analysts predict that iTeos Therapeutics will post -3.49 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Intech Investment Management LLC grew its stake in shares of iTeos Therapeutics by 13.4% during the 2nd quarter. Intech Investment Management LLC now owns 20,806 shares of the company’s stock worth $207,000 after acquiring an additional 2,466 shares during the period. CWM LLC grew its stake in shares of iTeos Therapeutics by 40.4% during the 2nd quarter. CWM LLC now owns 12,013 shares of the company’s stock worth $120,000 after acquiring an additional 3,459 shares during the period. Exchange Traded Concepts LLC grew its stake in shares of iTeos Therapeutics by 25.1% during the 1st quarter. Exchange Traded Concepts LLC now owns 17,308 shares of the company’s stock worth $103,000 after acquiring an additional 3,468 shares during the period. American Century Companies Inc. grew its stake in shares of iTeos Therapeutics by 5.9% during the 2nd quarter. American Century Companies Inc. now owns 78,949 shares of the company’s stock worth $787,000 after acquiring an additional 4,417 shares during the period. Finally, Wellington Management Group LLP grew its stake in shares of iTeos Therapeutics by 4.3% during the 4th quarter. Wellington Management Group LLP now owns 110,332 shares of the company’s stock worth $847,000 after acquiring an additional 4,563 shares during the period. Institutional investors own 97.16% of the company’s stock.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.